Observational studyClinical cardiology2025
Immune Checkpoint Inhibitor-Related Myocarditis: A Single Center Observational Registry.
Observational study in Clinical cardiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- A narrative review of immune checkpoint inhibitor-related cardiotoxicity in lung cancer: mechanisms, risk stratification, and clinical management.Journal of thoracic disease · 2026Review
- Cardiotoxicity of Immune Checkpoint Inhibitors and Chimeric Antigen Receptor T-Cell Therapy.Journal of cardiovascular development and disease · 2026Review
- Advancing precision cardio-oncology: multimodal surveillance and stratified management of immunotherapy-induced cardiovascular toxicity.Frontiers in cardiovascular medicine · 2026Review
- Prognostic risk factors and a survival prediction model for immune checkpoint inhibitor related myocarditis in patients with lung cancer: a multicenter study.Scientific reports · 2025Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
introductionImmune checkpoint inhibitors (ICIs) are associated with myocarditis, which is rare but has a high mortality. This study aimed to describe cases of ICI-related myocarditis at the University of Iowa Hospitals & Clinics and, in doing so, provide valuable insights into patient characteristics, treatment, and outcomes.
methodsThis single-center observational registry included cases of ICI-related myocarditis identified from 2009 to 2024. Data were collected retrospectively from electronic medical records and included demographics, cardiovascular risk factors, medications, and cancer characteristics. Between-group comparisons for continuous data were conducted using unpaired Student's t-tests or the Wilcoxon rank-sum test. Categorical data were analyzed with Fisher's exact test.
resultsEighteen patients were included. The mean age was 74 ± 9.4 years with 61% being male. Compared to controls, patients with ICI-related myocarditis had a significantly higher prevalence of coronary artery disease (36.8% vs. 7.5%, p = 0.01) and obstructive sleep apnea (33% vs. 10%, p = 0.03). They were less likely to have a normal sinus rhythm on baseline electrocardiogram (50% vs. 70%, p < 0.01) and more likely to suffer from a major adverse cardiac event (MACE) (38.9% vs. 2.5%, p < 0.01). Twelve (66.7%) of patients with ICI-related myocarditis also had myasthenia gravis-like overlap syndrome and 9 (50%) had myositis/rhabdomyolysis.
conclusionsICI-related myocarditis at a tertiary care center is rare with a calculated incidence of 0.48%. Despite this, the disease has a high incidence of MACE. Patients with pre-existing cardiovascular disease are at higher risk of developing ICI-related myocarditis. Careful cardiovascular monitoring in patients undergoing ICI therapy is warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.